GMA treatment resulted in decreased inflammation in blood and CSF. (A) Description of disease status in relation to age and treatments over time. GMA (int) indicates the interval of GMA in weeks for the indicated period, as specified by the numbers inside the boxes in the GMA row. GMA (week) indicates the number of weeks from GMA onset (0), specified by the numbers in italics below the boxes. For MRI, ND, and NF-L, the dashes indicate unchanged status compared with previous examination. The arrowheads pointing down indicate regression/decreased levels compared with the previous examination, whereas arrowheads pointing up indicate increased levels compared with the previous examination. The dashed lines next to each treatment indicate the treatment period. (B) NF-L and corresponding IL-17A protein levels in CSF. Results from only 1 NF-L enzyme-linked immunosorbent assay kit (from week 109 onward) are shown for simplicity because of different reference values and sensitivity of the 2 NF-L enzyme-linked immunosorbent assays used (see supplemental Materials and methods). IL-17A protein levels in plasma (C) and the percentages of IL-17A⁺ monocytes in peripheral blood mononuclear cells (PBMCs) (D) measured from week 115 onward. The interval of GMA in weeks is indicated in the boxes on top of the graphs in panels B-D. The dotted line indicates the mean value of controls (healthy), and the dashed line indicates +3 standard deviations from control mean. IL-17A protein levels in plasma (E) and percentage of IL-17A⁺ monocytes in PBMCs (F) in relation to the frequency of GMA. (G) Relative changes in plasma levels of IL-17A and IL-23 on weeks 326 (7 weeks before GMA termination) and 416 (18 months after GMA termination) as compared with week 115. CST, corticosteroids; DI, diabetes insipidus; PPBS, posterior pituitary bright spot; 6-MP, 6-mercaptopurine. The ESR values are presented as the mean value for the indicated period.